title: α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells.
abstract: α-Fetoprotein (AFP) is a tumour-associated antigen in hepatocellular carcinoma (HCC). The biological properties of AFP have been identified in its regulatory effects on immune responses of T cells and B cells. However, AFP effects on natural killer (NK) cells are still unclear. In this study, we examined the immunoregulation of AFP on NK activity. The cytolytic activity against K562 cells and Huh7 cells of NK cells co-cultured with AFP-treated dendritic cells (DCs) (AFP-DCs) was lower than that with albumin-treated DCs (Alb-DCs). Direct addition of AFP to NK cells did not alter the cytolytic activity of NK cells. Adding AFP inhibited the interleukin (IL)-12 production of DCs after stimulation with lipopolysaccharide (LPS) [Toll-like receptor (TLR)-4 ligand], or Poly(I:C) (TLR-3 ligand), but not IL-18 production. The mRNAs of IL-12p35 and IL-12p40 were significantly inhibited in AFP-DCs compared with Alb-DCs, but those of TLR-4 or TLR-3 were not. Transwell experiments revealed that soluble factors derived from DCs played roles in inhibition of the ability of activating NK cells by AFP-DCs. Adding the neutralizing antibody of IL-12 to NK cells co-cultured with Alb-DCs resulted in a decrease of cytolytic activity to the levels of NK cells co-cultured with AFP-DCs. Adding IL-12 to NK cells co-cultured with AFP-DCs resulted in an increase of cytolytic activity to the levels of NK cells co-cultured with Alb-DCs. These demonstrated that the impairment of IL-12 production from AFP-DCs resulted in inhibition of the ability of the activation of NK cells by DCs, and thus suggests a role of AFP in HCC development.
authors: Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
authors: M
authors: M
authors: Yamamoto
authors: T
authors: T
authors: Tatsumi
authors: T
authors: T
authors: Miyagi
authors: H
authors: H
authors: Tsunematsu
authors: H
authors: H
authors: Aketa
authors: A
authors: A
authors: Hosui
authors: T
authors: T
authors: Kanto
authors: N
authors: N
authors: Hiramatsu
authors: N
authors: N
authors: Hayashi
authors: T
authors: T
authors: Takehara
references: N Engl J Med. 2008 Jul 24;359(4):378-90
references: 18650514
references: Gastroenterology. 2001 Jan;120(1):250-60
references: 11208734
references: Nat Rev Immunol. 2003 Feb;3(2):133-46
references: 12563297
references: J Immunol. 2003 Nov 15;171(10):5423-9
references: 14607946
references: Immunity. 2008 Apr;28(4):571-80
references: 18394936
references: J Immunol. 2005 Mar 1;174(5):2457-65
references: 15728447
references: Clin Cancer Res. 2007 Aug 15;13(16):4677-85
references: 17699845
references: Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
references: 15508101
references: Hepatology. 1994 Jan;19(1):61-6
references: 7506227
references: Cancer Lett. 2000 Jan 1;148(1):49-57
references: 10680592
references: Immunology. 2007 May;121(1):1-14
references: 17386080
references: J Exp Med. 1978 Aug 1;148(2):360-72
references: 81256
references: Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12
references: 15508073
references: Nature. 1977 May 19;267(5608):257-9
references: 68439
references: Gastroenterology. 2004 Nov;127(5 Suppl 1):S232-41
references: 15508089
references: Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
references: 15508102
references: J Exp Med. 1975 Feb 1;141(2):269-86
references: 46267
references: Cancer Sci. 2008 Aug;99(8):1643-9
references: 18754878
references: Hum Immunol. 2008 Aug;69(8):490-500
references: 18619507
references: Immunol Rev. 2000 Apr;174:5-20
references: 10807503
references: Gastroenterology. 2006 Aug;131(2):461-9
references: 16890600
references: J Hepatol. 2002 Jun;36(6):734-41
references: 12044522
references: J Immunol. 2004 Feb 1;172(3):1333-9
references: 14734707
references: J Immunol. 2008 Apr 1;180(7):5109-17
references: 18354237
references: J Immunol. 2004 Aug 1;173(3):1772-8
references: 15265907